The Founder
A Mission Born from Necessity
The intersection of biology and binary.
Matt Hardy
Founder & CEO, NomosLogic Inc. — Salt Lake City, Utah
Matt Hardy established NomosLogic to create clinical genomics infrastructure merging consumer DNA data, real-time clinical support, and multi-omic analysis. The platform has mapped over 1.26 million clinical rules across 497,000 proprietary genomic nomenclature translations, providing variant classification and pharmacogenomic guidance in under 30 seconds.
As a systems architect with three decades of experience, Matt designed the core engine stack: COVENANT (genome resolution), TRINITY (multi-omic fusion), Hardy Bridge (cross-nomenclature translation), and PROTEUS (evolutionary drug resistance simulation). Ten patent applications have been filed through Wilson Sonsini Goodrich & Rosati.
Patient MH-001
Matt is Patient MH-001, the first validated clinical case on the platform. His own consumer DNA analysis identified compound heterozygous TPMT variants contraindicating certain chemotherapy drugs and CFTR variants associated with increased gastrointestinal cancer risk. An independent endoscopy confirmed colonic polyps and duodenal pathology matching platform predictions.
30 years software engineering (high-scale, high-availability architecture)
Deep academic background in biology and sciences
Architectural lead for platforms achieving over $1.8B enterprise value
Patient-first philosophy emphasizing proactive healthcare
“NomosLogic is the synthesis of foundational biological study and 30 years of engineering precision…to ensure that no one has to be their own researcher to get clear health answers.”
— Matt Hardy, Founder & CEO